Prostate neoplasm

Researchers are testing whether immediate curative treatment (surgery or radiotherapy, with or without hormone therapy) helps men aged 75 and older with high-risk, non-metastatic prostate cancer live longer and with better quality of life compared to conservative, symptom-focused…

Researchers are testing a procedure called irreversible electroporation in men with localized prostate cancer. The technique uses electrical pulses to destroy cancer cells in the prostate while aiming to avoid damage to nearby nerves and structures. The study will follow 10 men f…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This study tests a new combination of two drugs (tulmimetostat and JSB462) in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then comparing the combination to usual car…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…

This early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This study is testing a new drug called ADI-PEG20, which breaks down arginine (a nutrient cancer cells need), together with two chemotherapy drugs (carboplatin and cabazitaxel) in men with aggressive variant prostate cancer. The goal is to find the safest dose and check for side …

This study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…

This study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About…

Researchers are testing whether daily adaptive radiotherapy, which adjusts the radiation plan to each day's anatomy, causes fewer bladder and bowel side effects than standard radiotherapy in people with intermediate or high risk localized prostate cancer. The trial also compares …

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first t…

Researchers are testing a combination of two experimental drugs, JANX013 and JANX007, in men with metastatic castration-resistant prostate cancer, an advanced form that keeps growing despite hormone-lowering treatment. The Phase 1 trial gives both drugs by intravenous infusion to…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This trial investigates whether high doses of testosterone can shrink tumors in men with metastatic prostate cancer that no longer responds to standard hormone therapy and has mutations in DNA repair genes like ATM or CDK12. Participants receive monthly injections of high-dose te…

Researchers are testing a treatment plan for men with high-risk localized prostate cancer that combines whole-pelvis radiation given in five sessions, a high-dose radiation boost directly to the prostate, and two years of androgen deprivation therapy. The study aims to see how of…

This phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…

This phase II trial is testing two radioactive drugs, 225Ac-PSMA-617 and 177Lu-PSMA-617, combined with precise radiation therapy for prostate cancer that has returned and spread to a few spots in the body. The drugs target a protein on cancer cells and deliver radiation to kill t…

This study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…

This study investigates whether precisely targeted radiotherapy can delay the need for stronger drugs in men with prostate cancer that has started to grow in a few new spots while on systemic therapy. Participants have metastatic hormone-sensitive or castration-resistant prostate…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

Researchers are comparing two sequences of treatment for metastatic castration-resistant prostate cancer that carries certain DNA repair gene mutations. Participants receive either carboplatin first and olaparib second, or olaparib first and carboplatin second, switching after th…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…

This study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This clinical trial is testing an experimental drug called opevesostat (MK-5684), either alone or combined with other cancer drugs, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The study involves 220 participants and has t…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the fir…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …

This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

Researchers are testing two experimental oral drugs, TT-10 and TT-4, in adults with advanced solid tumors such as kidney, prostate, and lung cancers that have worsened after standard treatment or cannot receive it. The drugs block adenosine receptors, which tumors use to quiet th…

Researchers are testing whether men with high-risk localized prostate cancer can safely receive a shorter course of hormone therapy alongside focused, dose-escalated radiation to the prostate. The trial enrolls 30 men and uses an AI-based classifier to help tailor treatment. All …

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study is for men with prostate cancer that has spread to a few other parts of the body at diagnosis. It tests whether adding radiation therapy directly to those cancer spots (called metastasis-directed radiotherapy) can help keep the cancer under control longer than the usua…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This study tests whether adding a short, 30-day course of the oral hormone drug Relugolix to standard targeted radiation (SBRT) works better than radiation alone for men with intermediate-risk prostate cancer. About 60 men will be randomly assigned to one of the two treatments. T…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage trial tests a new oral drug called INR731, alone or with standard hormone therapy drugs, in 208 men with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the right dose, and see if the drug shows an…

This trial tests whether wrapping the nerves around the prostate with a special tissue allograft during surgery can reduce erectile dysfunction and incontinence. 25 men with localized prostate cancer will receive the wrap during nerve-sparing prostate removal. The study focuses o…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This phase 3 trial is testing whether adding the experimental drug xaluritamig to standard abiraterone helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not yet had chemotherapy will be randomly assigned to receive either …

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and …

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This study tests whether a 16-week supervised exercise program (circuit training with resistance, functional, and aerobic exercises) can improve frailty and muscle loss in 80 men with metastatic prostate cancer who are on hormone therapy. Participants must be pre-frail or frail. …

This early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

Researchers are testing whether adding darolutamide to docetaxel or cabazitaxel chemotherapy helps men with metastatic castration-resistant prostate cancer whose disease has worsened on a hormone-blocking drug. The trial enrolls about 245 men and randomly assigns them to receive …

This study tests a combination of two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—in men with advanced prostate cancer that has stopped responding to hormone treatments. The goal is to see if this combo can slow or stop cancer growth. …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This phase II trial tests whether adding bipolar androgen therapy (cycles of testosterone) to the standard Sipuleucel-T vaccine can boost the immune response in men with metastatic castration-resistant prostate cancer. About 26 participants will receive both treatments, and resea…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer course (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach works just as well at preventing the cancer from sprea…

This phase 2 trial tests an oral drug called pacritinib in 32 men with metastatic castrate-resistant prostate cancer that has worsened after standard treatments. The drug is taken twice daily, and the main goal is to see if it can delay cancer growth for at least six months. Part…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This trial tests whether a combination of a daily erectile medication, pelvic floor exercises, aerobic exercise, dietary advice, and mental health support can improve erectile function and urinary control in men after robot-assisted prostate removal for prostate cancer. Sixty-fou…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This trial is testing a daily adaptive radiation therapy for low to intermediate risk prostate cancer that spares the urethra. The goal is to reduce urinary side effects compared to standard radiation. About 132 participants will receive this tailored radiation, and their urinary…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to guide the body's immune cells to attack cancer cells. The trial will first find the safest dose…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This study is for men with a type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It tests whether adding a new drug called SX-682 to the existing drug apalutamide is safe and can shrink tumors or slow the cancer. About 78 men will …

This study tests whether adding targeted radiation to spots where prostate cancer has spread can help men whose cancer is already responding to hormone therapy. About 80 men with metastatic prostate cancer will be randomly assigned to get either standard care or standard care plu…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…

This early-stage trial is testing an experimental drug called SHR-6914 in men with prostate cancer that has spread to other parts of the body. The main goal is to see if the drug is safe and tolerable, and to find the right dose for future studies. Participants must have a confir…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-stage trial tests a new radioactive drug called 177Lu-FC516 in 13 men with advanced prostate cancer that has stopped responding to standard treatments. The drug is given every 6 weeks for up to 4 cycles. The main goals are to find the safest dose and check for side eff…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study tests a new way to give radiation for prostate cancer using only 2 treatments instead of the usual 39. Doctors will use MRI scans to see how the tumor responds after the first dose, then adjust the second dose to target the cancer more precisely. The goal is to see if …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through th…

This study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This phase II trial tests whether 6 months of androgen deprivation therapy (ADT) combined with dose-escalated radiotherapy can reduce the risk of distant metastasis in men with high-risk prostate cancer who have lower ARTERA scores. Participants receive standard ADT (degarelix, l…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metast…

This large Phase 3 trial is testing a new oral drug called opevesostat (MK-5684) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that has worsened after prior hormone therapy and chemotherapy. The study aims to …

This phase 3 trial is testing whether adding an experimental drug called rinzimetostat to the standard drug darolutamide can slow the progression of metastatic castration-resistant prostate cancer better than current treatments. The study enrolls men whose cancer has worsened aft…

This study tests whether a new combination of two drugs, inavolisib and enzalutamide, works better than standard treatments for men with metastatic castration-resistant prostate cancer that has progressed after one prior therapy. About 100 men will be randomly assigned to receive…

This study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the body's immune cells attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people t…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…

This study tests whether analyzing a patient's tumor DNA and RNA can help doctors select the most effective treatment for advanced prostate cancer that no longer responds to hormone therapy. About 474 participants will receive one of several drugs based on their genetic profile. …

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

This phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This phase 2 trial tests whether adding precise external beam radiation to standard radioligand therapy can better control metastatic prostate cancer that no longer responds to hormone therapy. About 120 participants will receive either standard treatment alone or combined with t…

This phase 3 trial tests a radioactive drug called lutetium-177 vipivotide tetraxetan in 450 men whose prostate cancer has returned and spread to a few spots after initial treatment. The drug targets a protein on cancer cells and delivers radiation directly to them. The goal is t…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This early-stage trial tests a new drug called CBP-1019 combined with standard chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have not responded to prior treatments. The goal is to find safe and effective doses. About 128 participants wi…

This early-phase trial tests an investigational drug called SRT-017 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug is designed to seek out and deliver radiation directly to cancer cells that carry a marker called PSMA. Rese…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This study tests whether adding a drug called relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 people whose cancer has not responded to standard treatments will take the study drugs for 24 weeks, then h…

This study tests a drug called tarlatamab in people with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either came back or didn't respond to prior treatments. About 32 participants will receive the drug to see if it can shrink tumors or slow the …

This early-stage trial is testing an experimental drug called JNJ-98768111 in people with advanced prostate cancer that has spread to other parts of the body. The drug is designed to seek out and attach to a protein called KLK2 on prostate cancer cells, delivering a toxic agent d…

This study tests an experimental oral drug called HLD-0915 in men with metastatic prostate cancer that has worsened after other treatments. The trial has two phases: Phase 1 checks safety and the best dose, while Phase 2 looks at how well it controls the cancer. About 190 men wil…

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This study is for men whose prostate cancer has come back in a few spots after radiation, but is still hormone-sensitive. Researchers want to see if adding a 12-month course of hormone therapy (ELIGARD) to targeted treatments like radiation or surgery helps keep the cancer from g…

This study tests a new drug called AZD0516, given alone or with other cancer drugs, in people with metastatic prostate cancer that has spread. The main goals are to check safety, find the best dose, and see early signs of tumor control. About 177 participants will take part acros…

This study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…

This phase 1 trial tests an experimental oral drug called HRS-5041 in men with metastatic castration-resistant prostate cancer, a form of the disease that keeps growing despite hormone therapy. Researchers aim to find the safest dose, measure how the body processes the drug, and …

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests a daily herbal supplement called INM176 (made from Angelica Gigas Nakai) in 45 men with prostate cancer whose PSA levels are rising after prior treatment or who are on active surveillance. The goal is to see if the supplement is safe and can stabilize or lower PS…

This study looks at whether irreversible electroporation (IRE) can safely and effectively treat recurrent pelvic tumors in people who cannot have surgery, radiation, or other local treatments. IRE uses electrical pulses to destroy cancer cells without cutting or heating tissue. R…

This study tests whether giving an extra, focused dose of radiation to the main tumor inside the prostate can improve cancer control in men with intermediate- or high-risk localized prostate cancer. Participants receive standard moderately hypofractionated radiotherapy (62 Gy in …

This study is testing two experimental drugs (AZD9574 and AZD2265) together in people with metastatic prostate cancer that has spread beyond the prostate. The goal is to see if the combination is safe and can shrink tumors or lower PSA levels. About 152 adults whose cancer has no…

This study tests a new drug called AZD2265, which delivers radiation directly to prostate cancer cells. It is for people with a type of advanced prostate cancer that no longer responds to hormone therapy. The trial compares the new drug to standard treatments to see if it can slo…

This trial tests whether a special PET-CT scan can spot aggressive prostate cancers that standard MRI fails to see. Men aged 50 and older with intermediate-risk prostate cancer and at least one MRI-invisible tumor will receive the scan; if it lights up the hidden cancer, they wil…

This phase 2 trial tests whether adding the targeted drug capivasertib to standard hormone therapy can shrink or destroy high-risk prostate tumors before surgery. The study enrolls 30 men with PTEN-loss prostate cancer, a marker of resistance to standard treatment. Participants r…

This phase 2 trial is testing whether an investigational oral drug called MRT-2359, when combined with the standard prostate cancer drug apalutamide, can lower PSA levels in men with castration-resistant prostate cancer. The study includes about 25 adults with a specific genetic …

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study is testing whether using MRI or CT scans to guide radiation therapy in real time can reduce urinary and bowel side effects for men who need radiation after prostate removal surgery. The treatment, called stereotactic body radiotherapy (SBRT), delivers precise high-dose…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This trial tests a combination of two advanced radiation techniques for men with intermediate- to high-risk prostate cancer that has not spread beyond the prostate. One technique, high-dose rate brachytherapy, places radioactive material directly into the tumor. The other, stereo…

This trial is testing whether adding the chemotherapy drug docetaxel after standard treatment (radiation or surgery) can improve outcomes for men with a particularly aggressive form of prostate cancer (Gleason score 9-10). Participants will either receive standard treatment alone…

This phase II trial tests a new radiation technique for low to intermediate risk prostate cancer. It uses an MRI-guided 'microboost' to deliver a higher dose to the tumor while lowering the dose to the rest of the prostate. The goal is to see if this approach is safe and causes f…

This registry tracks 2,500 men with prostate cancer who receive Vanquish therapy, a procedure that uses water vapor (steam) to destroy cancerous tissue. The goal is to see how well it controls the disease and what side effects occur over time in real-world settings. Participants …

This study looks at how well darolutamide (Nubeqa) plus standard hormone therapy works in Chinese men whose prostate cancer has become resistant to earlier treatment but hasn't spread. About 800 men will take part, and researchers will track PSA levels to see if the cancer is con…

This trial compares two treatment approaches for men with aggressive, metastatic prostate cancer that has stopped responding to hormone therapy and docetaxel. One approach uses a combination of two chemotherapy drugs (cabazitaxel and carboplatin), while the other uses a radioacti…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This phase 3 trial is testing whether adding low-intensity shockwave therapy to standard erectile dysfunction pills helps men recover erectile function more effectively after robotic prostate cancer surgery. The study involves 158 men who have undergone nerve-sparing surgery and …

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This trial tests whether tailoring prostate cancer therapy to the genetic makeup of a person's tumor can improve the response before surgery. Men with high-risk localized prostate cancer receive initial hormone therapy while their tumor is genetically analyzed, then are assigned …

This trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…

This trial is testing whether adding surgery to remove the prostate to standard drug therapy helps men with advanced, hormone-sensitive prostate cancer that has spread to multiple sites. Participants will receive either the usual drug treatment alone or the same drugs plus surger…

This phase III trial is testing whether adding the drug darolutamide and a precise, high-dose radiation technique (SBRT) to standard hormone therapy and radiation can help men with high-risk localized prostate cancer live longer without the cancer spreading. About 700 men will be…

This study looks at men whose prostate cancer has spread to a few spots in the body (oligometastatic). It compares standard radiation and hormone therapy alone versus adding the drug abiraterone for 8-9 months. The goal is to see if the extra drug improves quality of life and del…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This trial tests whether the drug rezvilutamide, taken alone for 48 weeks after prostate removal surgery, can prevent cancer from coming back in men at high risk of recurrence. Standard treatment often includes long-term hormone therapy with significant side effects. The study ai…

This study tests whether adding precise, high-dose radiation (SBRT) to standard second-generation antiandrogen drugs (enzalutamide or abiraterone) can better control prostate cancer that has spread to a few spots and stopped responding to hormone therapy. About 51 men with oligom…

This study investigates whether using magnetic resonance imaging (MRI) instead of standard CT scans to plan radiation therapy can improve treatment accuracy and reduce side effects. It enrolls adults with prostate, liver, or head and neck cancers who need radiation. Researchers w…

This trial investigates whether adding the hormone therapy apalutamide to high-precision radiation (SBRT) can drive prostate-specific antigen (PSA) levels extremely low in men with intermediate-risk prostate cancer. Participants receive apalutamide to block testosterone that fuel…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This trial tests a specialized radiation technique called SIB-VMAT for men with high-risk or very high-risk localized prostate cancer. The approach delivers a higher radiation dose to the tumor while giving a standard dose to nearby lymph nodes, all in 20 sessions over four weeks…

This study tests a three-part program to increase the use of precision oncology—genetic testing that guides personalized treatment—for veterans with advanced lung or prostate cancer. The program includes a patient education video, feedback to doctors on their testing patterns, an…

This study tests a new robot-assisted surgery for localized prostate cancer that leaves the full length of the urethra intact. The goal is to help men regain urinary continence faster after prostate removal. About 60 men with early-stage prostate cancer will undergo the procedure…

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …

This study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while recei…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This Phase 3 trial is testing whether adding pelvic radiotherapy to standard hormone therapy can delay cancer progression in men whose prostate cancer has spread to nearby lymph nodes after prostate removal surgery. About 372 participants will be randomly assigned to receive eith…

This study tests whether giving radiation to the para-aortic lymph nodes (located in the abdomen) can better control prostate cancer that has returned in a limited number of spots. Men with hormone-sensitive prostate cancer and up to five lesions seen on a PSMA PET/CT scan will r…

This early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…

This study is testing a new way to give radiation for high-risk prostate cancer that has not spread. One hundred men will receive a shorter, stronger radiation boost to the prostate along with standard pelvic radiation. The goal is to see if this approach is safe and does not cau…

This study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…

This study tests a laser treatment guided by MRI to destroy early-stage prostate cancer in men aged 40-80 with low to intermediate risk. The goal is to control the cancer and avoid more aggressive treatments like surgery or radiation. Researchers will check results with follow-up…

This study tests whether taking creatine supplements along with a home-based resistance training program can help men with metastatic prostate cancer maintain muscle mass and reduce fatigue. Two hundred participants will be randomly assigned to receive either creatine or a placeb…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This study tests a precise radiation treatment (MR-guided high-dose-rate brachytherapy) for men whose prostate cancer has returned in the prostate bed after previous radiotherapy. About 20 participants will receive this targeted therapy to see if it can control the cancer with ac…

This study looks at men with high-risk prostate cancer that appears on only one side of the prostate. During robotic surgery to remove the prostate, doctors will either remove lymph nodes from both sides of the pelvis or just the side with cancer. The goal is to see if removing f…

This study tests an internet-based program called iLIVE that combines weight loss coaching and online exercise classes for men who have had hormone therapy for prostate cancer. The goal is to see if it can reduce obesity and frailty, which are common side effects of treatment. Re…

This study tests whether a single, very high dose of precisely targeted radiation can safely treat intermediate-risk prostate cancer. About 200 men will receive one 24-Gy dose to the prostate, with a possible extra boost to the main tumor. Researchers will monitor side effects, q…

This phase 3 trial is testing whether taking aspirin and atorvastatin (a common cholesterol-lowering drug) can help men with castrate-resistant prostate cancer live longer. The study plans to enroll 1210 participants who are starting their first treatment for this advanced stage.…

This Phase 3 trial tests whether adding darolutamide (Nubeqa) to standard hormone therapy (ADT) helps men with metastatic prostate cancer who are too frail for stronger treatments. About 300 participants will receive either darolutamide or a placebo, plus ADT. The goal is to see …

This phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…

This study is testing a new, shorter radiation treatment for men with early-stage prostate cancer. Instead of the usual 5 sessions, doctors will give 3 high-dose radiation treatments. The goal is to see if this approach is safe and causes fewer side effects while still controllin…

This study tests whether a high dose of testosterone combined with the chemotherapy drug carboplatin can help men with a specific type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 30 men with a genetic defect called homologous recombi…

This study compares a standard robot-assisted prostate removal surgery to a newer, pelvic fascia-sparing approach that aims to preserve nerves and support structures. Researchers will enroll 600 men with localized prostate cancer to see if the new technique offers similar cancer …

This study tests a new drug called PF-07248144, alone or combined with other cancer treatments, in people with advanced breast, prostate, or lung cancers that have not responded to standard therapy. The trial aims to find safe doses and check for early signs of tumor shrinkage. A…

This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…

This phase 2 trial tests Enhertu, a targeted drug, in 60 men with HER2-positive prostate cancer that has spread and stopped responding to hormone therapy and newer drugs like abiraterone. Participants must have tried or refused chemotherapy. The study measures tumor shrinkage and…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study looks at whether proton therapy can safely treat cancers that return after standard radiation. Proton beams are more targeted than traditional X-rays, so they may deliver stronger doses to the tumor while sparing healthy tissue. Researchers will track side effects and …

This study compares two treatments for men with intermediate-risk prostate cancer: focal HIFU (a targeted ultrasound that destroys only the tumor) and radical prostatectomy (complete removal of the prostate). The goal is to see which approach offers better value for money and qua…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…

This early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study tests a smarter way to give radiation to men whose prostate cancer has come back after surgery. Using advanced scans, doctors will give higher radiation doses to the spots where cancer is active and lower doses to healthy areas. The goal is to control the cancer while …

This trial tests whether giving radiation every other day (5 sessions total) is as safe as the standard daily schedule (20 sessions) for men who have had prostate cancer surgery. The study involves 204 participants across multiple centers. The main goal is to see if the shorter s…

This study tests a new type of radiation therapy for men with prostate cancer that has spread to lymph nodes in the abdomen or pelvis. The treatment uses daily CT scans to adjust the radiation beam precisely to the tumor and nearby at-risk areas. The goal is to control the cancer…

The THUNDER trial is testing whether using advanced PET scans and a genetic test (Decipher) can help doctors choose the right treatment for high-risk prostate cancer. About 493 men will either get stronger treatment if their scans or genetic score show high risk, or less intense …

This early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…

This study is testing a new, shorter way to treat prostate cancer using proton therapy. Instead of the usual 5 sessions, researchers want to see if just 2 sessions are as safe and effective. The goal is to make treatment faster and more affordable while keeping side effects low. …

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researche…

This study compares two types of radiation therapy (proton vs. photon) given after prostate removal surgery. The goal is to see if proton therapy causes fewer bowel problems and improves quality of life. About 900 men with prostate cancer will be randomly assigned to one of the t…

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at s…

After surgery to remove prostate cancer, cancer cells sometimes remain at the edge of the removed tissue, which can lead to the cancer returning. Researchers are testing a light-based imaging method called hyperspectral imaging to examine the removed prostate and identify cancer …

This study is testing whether a radioactive tracer called 18F-DCFPyL, used during a PET/CT scan, can better detect where prostate cancer has returned in men whose PSA levels are rising after initial treatment. About 350 men will be followed for up to 5 years with regular scans an…

This study tests a new PET/CT imaging agent called 68Ga-NYM032 in 232 men with suspected prostate cancer recurrence after initial treatment. Participants have rising PSA levels, and the scan aims to accurately locate any remaining cancer. The goal is to see how well the scan dete…

This phase 3 trial tests a new radioactive imaging agent, 64Cu-SAR-bisPSMA, to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer will receive a single injection of the agent before their scheduled prost…

This study tests whether a new type of ultrasound, called transperineal micro-ultrasound, can better detect prostate cancer during biopsy. Unlike standard ultrasound, this method uses higher frequency sound waves to create clearer images. Researchers will enroll 138 men scheduled…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

Researchers are testing a device called the CARE phantom system to see if it can make prostate MRI measurements more consistent across different scanners. The study includes men aged 18 and older who are undergoing prostate cancer investigation and have suspicious lesions on MRI.…

This early study tests a new radioactive tracer called 68Ga-FC516 in 10 healthy adults and people with prostate cancer. The goal is to see if it is safe and how well it finds tumors on PET/CT scans compared to existing tracers. The results will help improve prostate cancer diagno…

This study tests whether a special PET scan using fluciclovine can help doctors decide on treatment for men whose prostate cancer has returned after initial treatment, but whose standard PSMA PET scan was unclear or negative. About 142 men will receive the fluciclovine PET scan, …

Researchers are testing whether a radioactive tracer called 68Ga/18F-PSMA/PSFA can improve PET/CT scans for finding tumors in people with PSMA-related cancers, including prostate and liver cancer. The study will enroll 500 adults with suspected, newly diagnosed, or previously tre…

Prostate biopsies can misjudge cancer severity up to 40% of the time. This trial tests a new needle that collects more tissue than standard ones, aiming to give pathologists a clearer sample. Researchers will compare tissue amount and quality from both needles in 200 men with sus…

This study is testing a blood test called Proclarix to see if it can better identify men with aggressive prostate cancer before they have a biopsy. About 500 men aged 40-75 with certain PSA levels will give a blood sample before their scheduled biopsy. The test results will be co…

This study tests whether taking multiple MRI scans before, during, and after standard radiation therapy can help doctors see how tumors change. Researchers will enroll people with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer, or pediatric glioma. The g…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study compares a new artificial intelligence (AI) system to radiologists for reading prostate MRI scans to detect cancer. About 130 men who are already scheduled for a prostate biopsy will have their MRI read by both the AI and a radiologist. The goal is to see if the AI can…

This study tests a new software tool that automatically analyzes MRI images of the prostate to find cancer areas that doctors might miss. About 180 people with known or suspected prostate cancer will get an MRI and then a targeted biopsy. Researchers will compare the software's a…

This trial tests whether taking biopsy samples from only the side of the prostate where an MRI shows a suspicious lesion can match the standard approach of sampling both sides. Men with suspected prostate cancer and a single MRI lesion will be randomly assigned to receive either …

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This trial compares two ways of taking prostate tissue samples in men with suspicious MRI findings: through the rectum (transrectal) or through the skin between the scrotum and anus (transperineal). Both methods use MRI images to guide the biopsy needle. The main goal is to see i…

This study investigates whether a blood test (liquid biopsy) can detect prostate cancer early by looking for tumor cells and genetic material in the blood. Researchers will compare blood samples from men with suspected prostate cancer to those without the disease. The goal is to …

This early-stage study tests a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal is to see if it is safe and can help detect cancer that has spread or come back. Participants receive one injection and then undergo PET scans to measure rad…

This study tests a new imaging approach for people with advanced breast or prostate cancer. It uses two radioactive tracers to find tumors that have a specific protein (GRPR). The goal is to see if this method is safe and can help doctors see where the cancer is in the body. Abou…

This study tests whether combining two advanced imaging techniques (micro-ultrasound and MRI) during prostate biopsy can find more aggressive cancers than the current standard approach. About 400 men with suspected prostate cancer will participate. The goal is to improve detectio…

This study compares a newer PSMA PET scan to the standard MRI for staging prostate cancer in men eligible for focal therapy (treatment that targets only the tumor). About 138 men with early-stage prostate cancer will be randomly assigned to get the PSMA PET scan or not. The goal …

This phase 2 trial tests whether a radioactive tracer called 64Cu-DOTA-AE105 can accurately show the aggressiveness of prostate cancer on a PET scan. About 168 men with low- to intermediate-risk prostate cancer will receive the tracer and undergo imaging. The goal is to see if th…

This study tests a new microscope called LaserSAFE that scans the removed prostate during surgery to see if cancer cells are at the edge. If it works well, surgeons can decide right away whether to spare nearby nerves. About 693 men with prostate cancer will take part, and the st…

This study tests two advanced imaging techniques, PSMA PET/CT and MRI-RSI, against the standard MRI to see which finds and outlines prostate tumors most accurately. Fifty men with newly diagnosed, higher-risk prostate cancer will undergo all scans and a targeted biopsy. The goal …

This study aims to develop a blood test that detects RNA from tiny particles (exosomes) to predict if prostate cancer has spread to the bones. Researchers will analyze blood samples from 1,000 men with newly diagnosed prostate cancer and compare results with PSMA PET scans. The g…

This study is testing whether taking a delayed PET/CT scan 2-3 hours after injection of a radioactive tracer can better detect aggressive prostate cancer compared to the standard 60-minute scan. Researchers will enroll 1,000 men with suspected prostate cancer who have not yet had…

This study tests a custom electrical impedance probe that measures tissue properties during prostate removal surgery. The goal is to see if it can instantly detect any cancer left behind, helping surgeons remove it all in one go. Two hundred men with prostate cancer will take par…

This study tests whether combining two types of scans (PET and MRI) before a prostate biopsy can more accurately find serious prostate cancers while avoiding unnecessary biopsies for low-risk cancers. About 167 men with suspected prostate cancer will receive the combined scan, an…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study follows men who had a negative prostate cancer screening about five years ago. They will undergo a repeat MRI and PSA test to see if any clinically significant prostate cancers have developed. The goal is to learn whether repeat screening is valuable and how often it s…

This study tests whether cannabidiol (CBD) can reduce the need for strong painkillers (opioids) in people with end-stage prostate cancer that has spread and no longer responds to standard treatments. About 58 participants will receive either CBD or a placebo three times daily for…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study looks at whether adding local anesthesia (numbing medicine) during a prostate biopsy, while patients are already sedated, reduces pain after the procedure. About 800 men will take part. The goal is to see if this simple change can lower pain scores, cut down on painkil…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This study tests a device called the Axonics SNM System, which uses mild electrical pulses to calm the nerves that control the bladder. It is for men with overactive bladder, including those with urgency incontinence or frequent urination. The trial will enroll 150 men and track …

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This phase 2 trial tests whether a low dose of naltrexone (LDN) can reduce fatigue in men with prostate cancer who are on hormone therapy (ADT). The study will enroll 60 participants and measure fatigue, quality of life, and safety. It is not yet recruiting.

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…

This study tests whether a small device that sends mild electrical pulses through the skin (TENS) can reduce pain during a prostate biopsy. About 140 men will get either a real TENS device or a fake one, along with standard numbing medicine. The goal is to see if TENS makes the p…

This trial tests whether a digital program called E-Mergir can improve sexual and mental well-being in men who have survived prostate cancer. Many survivors face lasting sexual difficulties and emotional distress, yet few have access to tailored support. The program, delivered th…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This trial investigates whether a laser surgery called HoLEP, which removes excess prostate tissue to improve urinary symptoms, can improve quality of life when performed before radiation therapy in men with both prostate cancer and bothersome lower urinary tract symptoms. The st…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This study tests whether applying a powder called ARISTA AH during robotic prostate removal can reduce blood loss and help preserve erectile function. About 362 men with prostate cancer will be randomly assigned to receive the powder or standard care. The goal is to see if the po…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study looks at whether saving a small extra artery to the penis during robotic prostate cancer surgery can help men recover erections. About 1 in 3 men have this artery, and the study will use MRI scans to find it before surgery. Researchers will follow 20-40 men for a year …

This pilot study is testing a new way to give radiation for prostate cancer that uses an MRI machine to guide the treatment. The goal is to give a lower dose of radiation to the whole prostate while giving a higher dose only to the main tumor, which may reduce side effects like u…

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…

This study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …

This study tests whether a mobile app with educational videos, pelvic floor exercises, and reminders can improve recovery of bladder control and erectile function in men after prostate cancer surgery. About 78 men scheduled for prostate removal will be randomly assigned to either…

This study is testing whether giving a lower dose of radiation in just two sessions can reduce side effects for men with intermediate-risk prostate cancer. All participants will be treated on a special MRI-guided machine (MR-Linac) that adapts the radiation daily. The main goal i…

This study is for men with prostate cancer that has spread to other parts of the body. It compares two different schedules of radiation to the prostate: one given every other day for 2 weeks, and another given once a week for 6 weeks. The goal is to see if the shorter schedule ca…

This study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…

This study tests a telehealth program called ENGAGE for people with stage IV breast, prostate, lung, or colorectal cancer. The program helps manage symptoms like pain, fatigue, and distress that interfere with daily life. About 190 participants will be randomly assigned to ENGAGE…

This study tests whether a program of targeted exercise and psychological support before cancer treatment (called prehabilitation) can help patients with solid tumors recover better physically and emotionally. Researchers will compare this program to standard care in 125 adults w…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study collects blood, urine, saliva, and tumor tissue from 3,000 men with prostate cancer to investigate genetic changes that cause the disease. Participants may also undergo imaging and answer quality-of-life questions. The goal is to better understand prostate cancer and l…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study uses detailed MRI scans and targeted biopsies to investigate why some prostate cancers come back after radiation therapy. Researchers will follow 300 men who are scheduled for radiation or whose cancer has returned after earlier treatment. The goal is to better underst…

The PROMISE registry collects health information and saliva samples from people diagnosed with prostate cancer at any stage. Researchers test the samples for inherited gene variants that raise cancer risk and follow participants for at least 15 years. The goal is to learn how the…

This study is testing a new algorithm that uses a liquid biopsy (a simple blood test) to find HRR gene mutations in patients with metastatic prostate cancer. It is for patients whose tumor tissue is not available or is inadequate for standard testing. The goal is to see if this m…

This study looks at whether artificial intelligence (AI) can help radiologists find prostate cancer on MRI scans. About 150 men aged 55-80 who are scheduled for a prostate biopsy will take part. The AI software will be compared to radiologists reading the scans alone. The goal is…

This study is testing a new PET-CT scanner that takes high-resolution images of tissue removed during cancer surgery. Researchers want to see if these images match lab results and help surgeons make better decisions. The study will include 850 people with prostate, breast, head a…

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid, prostate, or neuroendocrine cancers. The goal is to provide researchers with valuable data to better understand these treatments. No new …

Researchers at University Hospital, Strasbourg, are developing 3D tumor models grown from patient tissue to study kidney, bladder, and prostate cancers. The study collects tumor samples and a small blood sample from about 100 adults with these cancers. Scientists use the blood to…

This study is testing whether two types of PET scans can better detect where prostate cancer has spread in the body. About 300 men with prostate cancer that is getting worse will receive injections of a radioactive tracer and then be scanned. The goal is to see if these scans are…

This study will follow 700 men with high-risk localized or metastatic prostate cancer to collect detailed information on how they are treated in everyday practice. Researchers will track treatments, side effects, quality of life, and disease progression over time. The goal is to …

This study looks at how the head-down position and gas used during robotic prostate surgery affect pressure inside the eye. Researchers will measure eye pressure with a simple ultrasound in 50 men having either robotic or open prostate surgery. The goal is to understand these cha…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study is gathering medical records and imaging data from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in scans that could help diagnose and treat the disease more effectively. No new drugs or procedures are being tested.

This study is collecting blood, urine, tissue samples, and health information from 300 men with advanced prostate cancer. Researchers hope to build a resource that will help them learn more about the disease and improve future care. Participants will not receive any experimental …

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This study tracks 500 men aged 30-75 who have specific genetic changes linked to prostate cancer but have not been diagnosed. Researchers will monitor their health over time using yearly exams, blood tests, and MRI scans to understand how these genes affect cancer risk. The goal …

This study compares two levels of patient navigation—high-intensity versus low-intensity—to see which helps more people with prostate or kidney cancer enroll in clinical trials. About 90 participants will be randomly assigned to receive either extra support from a patient navigat…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study follows 3,000 men with early-stage prostate cancer who have chosen active surveillance (close monitoring instead of immediate treatment). The goal is to discover biological markers that can tell apart aggressive cancers from slow-growing ones. Researchers hope this wil…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study uses special PET/CT scans to see how advanced prostate cancer becomes resistant to newer hormone therapies like enzalutamide or abiraterone. Researchers will track changes in cancer lesions over time in 25 participants. The goal is to better understand resistance patte…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study tracks 270 men with metastatic hormone-sensitive prostate cancer to see how faithfully they take their apalutamide pills over the first year. Researchers will use questionnaires to measure adherence and identify who is at risk of skipping doses. The goal is to learn wh…

This study explores whether artificial intelligence, combined with large-scale healthcare records, can help personalize radiotherapy for prostate cancer. By analyzing data from 15,000 patients, researchers aim to find ways to reduce damage to healthy tissue without compromising t…

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This research project tracks men treated with a technology called High-Intensity Focused Ultrasound (HIFU) for prostate cancer or an enlarged prostate. The goal is to see how well this treatment controls disease and affects urinary and sexual function over 10 to 20 years. By coll…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study looks at how a man's age, health conditions like diabetes or high blood pressure, and sexual function before surgery affect the return of erections after nerve-sparing robotic prostatectomy for prostate cancer. Researchers will track 300 patients for a year, collecting…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This study explores how patients and healthcare providers view the use of genetic risk profiling for prostate cancer in everyday clinical practice. Through interviews, researchers aim to understand the benefits, challenges, and needs associated with receiving and delivering genet…

This study looks at why some older adults with serious conditions like cancer or fractures become vulnerable or frail. Researchers will follow about 1500 patients to find out how common different causes of vulnerability are and how they affect outcomes like survival and quality o…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…

This study tests whether a new online tool, called BeSpoke, helps men with newly diagnosed localized prostate cancer make better treatment decisions. The tool gives personalized information about different treatments and their likely outcomes. Researchers will compare men who use…

This pilot study tests whether a new type of CT scanner, called photon-counting CT, can clearly show the urethra in prostate cancer patients without inserting a catheter. Currently, catheters are often needed to see the urethra during radiotherapy planning, which can be uncomfort…

This study tests whether a large language model (a type of AI) can accurately stage prostate cancer by reading Chinese PSMA PET/CT reports. Researchers will compare the AI's staging against expert doctors' assessments using thousands of de-identified reports. The goal is to see i…

This study follows 700 men with prostate cancer that has spread to up to 10 spots in the body (oligometastatic). All receive radiotherapy to the prostate and to each visible metastasis, along with standard systemic therapy. Researchers collect real-world data from medical records…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This registry gathers real-world information from thousands of men treated with high-intensity focused ultrasound (HIFU) for prostate cancer using the Focal One device. The goal is to monitor safety and track cancer control through routine PSA tests and MRI scans. By collecting d…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study looks at whether men with prostate cancer who have hot flashes from hormone therapy will consistently wear a smartwatch to track their symptoms. For 4 weeks, 18 participants will wear the watch, log hot flashes by pressing a button, and complete daily surveys. The goal…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study is testing whether a new genetic test (called PCAI ImmunoScore) can predict how well men with high-risk prostate cancer will respond to the drug darolutamide before surgery. About 100 participants will take darolutamide for 3-4 months, then have their prostate removed.…

This study compares three different blood tests (CellSearch, Parsortix, and SmartCatch) to see which one best detects circulating tumor cells in patients with metastatic breast or prostate cancer. Researchers will take blood samples from 54 patients before they start a new treatm…

This study follows men with low-risk prostate cancer who have chosen active surveillance—monitoring the cancer over time rather than treating it right away. Researchers will collect data for years to learn which signs predict that the cancer may become aggressive. The goal is to …

This study follows 837 men with high-risk prostate cancer who choose either robot-assisted surgery or radiation therapy (with or without hormone therapy). Researchers will compare quality of life, side effects, and cancer control over time. The goal is to help patients and doctor…

This study is developing an AI system that tracks tumors and organs during radiation therapy without needing physical markers. Researchers will use existing patient data to train and test the AI. If it works, it could help doctors target radiation more accurately. The study invol…

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…

This study aims to validate a gene test that identifies oxygen-starved (hypoxic) tumours in bladder and prostate cancer patients. About 30 participants will provide tumour samples and blood, and some will have MRI scans. The goal is to see if this test can help doctors choose mor…

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study looks at whether a specific gut bacterium, Akkermansia muciniphila, can predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will collect stool and blood samples from 52 men over three months to track…

This study interviews 24 men with prostate cancer to learn how they feel about breast-related side effects, such as gynecomastia (enlarged breasts), from treatment. The goal is to understand what matters most to patients when choosing therapies. Results will help design a future …

This study is testing whether a special type of scan called PSMA PET can better monitor how prostate cancer responds to treatment. Researchers will scan 110 men with high-risk prostate cancer before and after treatment to see if changes in the scan match standard measures like PS…

This study compares three surgical methods for removing the prostate in men with prostate cancer: robot-assisted laparoscopy, standard laparoscopy, and open surgery. Researchers will track urinary and erectile function before and after surgery in 2,000 participants. The goal is t…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This study aims to describe the characteristics of prostate cancer in Algeria, including patient demographics, symptoms, diagnosis methods, and treatments. Researchers will collect data from 2,000 men aged 19 and older with confirmed prostate cancer. The goal is to better underst…

This study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…

This study follows 500 men who had their prostate removed for cancer. Researchers check PSA levels soon after surgery to see if they can predict if the cancer will come back or spread. No new treatments are given—just standard care and observation.

This study follows 64 men with localized prostate cancer who undergo laparoscopic radical prostatectomy (keyhole surgery to remove the prostate). The goal is to track any complications that occur from the day of surgery up to 30 days later. By understanding how often problems hap…

This study looks at how SPECT imaging can help doctors measure the amount of radiation reaching healthy organs during certain cancer treatments. About 80 adults with advanced prostate or other cancers will get extra SPECT scans before and after their standard radiation therapy. T…

This study compares regular MRI scans to standard care for men with low- to medium-risk prostate cancer who choose active surveillance (monitoring instead of immediate treatment). The goal is to see if MRIs can detect cancer progression earlier and more accurately, potentially re…

This study aims to see if specially trained radiographers can make decisions about prostate MRI scans as well as radiologists. The goal is to reduce the need for contrast injections and extra scans, making care faster and more efficient. The study will involve 1600 patients and c…

This registry study is collecting data from 2,800 cancer patients treated with ion beam therapy (protons and carbon ions) at MedAustron. Researchers will track tumor response, survival, side effects, and quality of life over time. The goal is to better understand the real-world b…

This study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…

This study is testing whether a special type of PET scan (PSMA PET) can predict how prostate cancer will progress in people who are newly diagnosed and have not yet had any treatment. Researchers will follow 1000 participants for at least 2 years to see if the scan results can fo…

This study is creating a large registry of 1,500 men with newly diagnosed prostate cancer. Researchers will track their health, side effects, and quality of life over time to better understand how different treatments affect patients. The goal is to build a platform for future st…